Volume 12 Supplement 1
Evaluation of methods to adjust for treatment switching in clinical trials
© Fox et al; licensee BioMed Central Ltd. 2011
Published: 13 December 2011
Treatment switching in clinical trials dilutes estimates of treatment effect which is problematic in decision making, especially in an economic context. In one example 75% of patients crossover from the randomised treatment which emphasises the need to address such bias. We consider methodologies that compensate for this bias.
The methods assessed are; intention to treat (ITT), per-protocol (PP), adjusted Cox model , causal proportional hazards estimator , rank-preserving structural failure-time models (RPSFT) , iterative parameter estimation (IPE) , parametric randomisation based method , and the less well known inverse probability of treatment weighting (IPTW) .
Survival data having an underlying Weibull distribution was simulated and designed such that probability of switching for patient subgroups could be varied within treatment-arms. Other subgroup characteristics could be controlled and 24 scenarios with varied levels of bias were analysed. A review of submissions to the National Institute of Clinical Excellence was performed and used to inform the scenario parameters.
The RPSFT and IPE methods returned the lowest biases, <8%, in all scenarios. The estimates of the parametric randomisation based method were often far less variable than other methods but were subject to erratic behaviour with extreme biases observed. The other methods performed poorly in general, with biases of up to 50% not uncommon. In particular the IPTW method over-compensates in most scenarios.
Under these conditions the results clearly identified the RPSFT and IPE methods as most consistent and accurate, with the latter the more consistent of the two. None of the other methods returned consistent results, and as such cannot be recommended.
Further avenues of investigation include exploring the effect of other underlying survival distributions, extending from univariate models to adjust for other covariates, and extending from situations where just control-arm patients switch to scenarios with multidirectional cross-over.
- Law , Kaldor J: Survival analyses of randomised clinical trials adjusted for patients who switch treatment. Stat Med. 1996, 15: 2069-2076.View ArticlePubMedGoogle Scholar
- Loeys T, Goetghebeur E: A causal proportional hazards estimator for the effect of treatment actually received in a randomised trial with all-or-nothing compliance. Biometrics. 2003, 59 (1): 100-105.View ArticlePubMedGoogle Scholar
- Robins J, Tsiatis A: Correcting for non-compliance in randomised trials using rank preserving structural failure time models. Communication in Statistics-Theory and Methods. 1991, 20 (8): 2609-2631.View ArticleGoogle Scholar
- Branson M, Whitehead J: Estimating a treatment effect in survival studies in which patients switch treatment. Stat Med. 2002, 21: 2449-2463.View ArticlePubMedGoogle Scholar
- Walker S, White I, Babiker A: Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment. Stat Med. 2004, 23: 571-590.View ArticlePubMedGoogle Scholar
- Hernan M, Brumback B, Robins J: Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000, 11 (5): 561-570.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.